TOPLINE

Among women with obesity, or overweight plus at least one obesity-related complication, orforglipron, an oral non-peptide GLP-1 receptor agonist, led to greater reductions in body weight and waist circumference than with placebo, regardless of menopausal status.

METHODOLOGY

• Researchers conducted a post hoc analysis of ATTAIN-1, which enrolled patients with overweight or obesity but without diabetes, and ATTAIN-2, which enrolled patients with overweight or obesity and type 2 diabetes, to evaluate how orforglipron affects body weight in women by menopausal stage; patients with overweight also had at least one weight-related complication.
• The drug had already shown significant weight reductions in both trials.
• The analysis drew on female participants and split them into premenopausal, perimenopausal, and postmenopausal subgroups; subgroup sizes ranged from 10 to 225 across the two studies.
• Assessments included changes in body weight, waist circumference, waist-to-height ratio, and the proportion of women who lost at least 5%, 10%, 15%, or 20% of their body weight at week 72.

TAKEAWAY

• In ATTAIN-1, women lost 12.81%, 14.38%, and 14.07% of their body weight with 36 mg orforglipron compared with 0.25%, 1.02%, and 0.62% on placebo if they were premenopausal, perimenopausal, or postmenopausal, respectively (P < .001 for all).
• In ATTAIN-2, women lost 11.30%, 8.88%, and 13.62% of their body weight on 36 mg orforglipron vs 2.88%, 1.57%, and 2.00% on placebo if they were premenopausal, perimenopausal, or postmenopausal, respectively (P < .05 for all).
• More than 80% of women in ATTAIN-1 who took orforglipron lost at least 5% of their body weight, irrespective of their menopausal stage, compared with roughly 20%-25% who took placebo (P < .001 for all).
• Significantly more women treated with orforglipron shifted into a lower waist-to-height ratio category compared with placebo, across most menopausal subgroups in both trials.

IN PRACTICE

"These findings underscore OFG's [orforglipron] efficacy in managing obesity across different menopausal stages," the authors wrote.

SOURCE

The study was led by Andreea Ciudin Mihai, Hospital Universitari Vall d'Hebron in Barcelona, Spain, and will be presented at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting in Milan, Italy.

LIMITATIONS

No limitations were explicitly mentioned in the conference abstract.

DISCLOSURES

The study was supported by Eli Lilly and Company, the manufacturer of orforglipron. All authors disclosed being employees of the company.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.